Please login to the form below

Not currently logged in
Email:
Password:

EMA Road Map consultation

The European Medicines Agency (EMA) has launched a public consultation on its Road Map to 2015, outlining its priorities for the next five years

The European Medicines Agency (EMA) has launched a public consultation on its Road Map to 2015, which outlines its priorities for the next five years and continues its previous five-year Road Map initiative.

European and international partners, stakeholders, including patients' and doctors' organisations as well as the pharmaceutical industry, and the public are invited to make their views known on the document, entitled The European Medicines Agency Road Map to 2015: The Agency's contribution to Science, Medicines, Health.

Building on the achievements of the previous Road Map initiative, covering 2005 to 2010, the focus of the new Road Map is on continuous high-quality delivery of the Agency's core business in an increasingly complex regulatory and scientific environment.

  • In addition, the document proposes three priority areas for future actions to strengthen the Agency's role in protecting and promoting human and animal health in the European Union. These include: Addressing public health needs by: stimulating research and medicines development in areas of unmet medical needs or for neglected and rare diseases; facilitating new and innovative approaches to the development of medicines; implementing effective preparedness plans to deal with public health threats  
  • Facilitating access to medicines by: addressing the high attrition rate during the development process of medicines; improving the Agency's model for the assessment of benefits and risks of medicines; improving the quality and scientific and regulatory consistency of the medicines review process
  • Optimising the safe use of medicines by: strengthening the evidence base on the benefits and risks of a medicine following its authorisation; applying novel pharmacovigilance methods and risk minimisation tools; by taking patient experience into account or improved decision making; becoming a reference point on information about medicines evaluated by the Agency.

Comments should be sent using the Agency's comments form by April 30, 2010 to: roadmap@ema.europa.eu

Final adoption is expected to take place in December 2010.


 

3rd February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics